George and colleagues present a case report, in which a single PD-L1-negative patient received pembrolizumab and experienced disease stability in upper-tract urothelial carcinoma (UTUC) for 20 months [40]. Here, CD274 is linked to renal pelvis/ureter urothelial carcinoma.